Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

A breast cancer prediction model incorporating familial and personal risk factors.

Tyrer J, Duffy SW, Cuzick J.

Stat Med. 2004 Apr 15;23(7):1111-30. Erratum in: Stat Med. 2005 Jan 15;24(1):156.

PMID:
15057881
2.

Models of genetic susceptibility to breast cancer.

Antoniou AC, Easton DF.

Oncogene. 2006 Sep 25;25(43):5898-905. Review.

PMID:
16998504
3.

Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.

Fu R, Harris EL, Helfand M, Nelson HD.

Stat Med. 2007 Apr 15;26(8):1775-87.

PMID:
17243094
4.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

5.

Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.

Pasini B, Casalis Cavalchini GC, Genovese T, Manoukian S.

J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):23-9.

PMID:
12585650
6.

Screening and follow-up of the patient at high risk for breast cancer.

Willey SC, Cocilovo C.

Obstet Gynecol. 2007 Dec;110(6):1404-16. Review.

PMID:
18055740
7.

Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.

Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Brémond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, Léoné M, Chauvin F, Easton DF, Lenoir GM, Lasset C.

Genes Chromosomes Cancer. 2005 Aug;43(4):404-13.

PMID:
15887246
8.

Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.

Fasching PA, Bani MR, Nestle-Krämling C, Goecke TO, Niederacher D, Beckmann MW, Lux MP.

Eur J Cancer Prev. 2007 Jun;16(3):216-24.

PMID:
17415092
9.

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.

Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG.

Eur J Cancer. 2006 May;42(8):1143-50. Epub 2006 Apr 27.

PMID:
16644204
10.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
11.

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. Epub 2005 Oct 27.

PMID:
16261400
12.

Modeling familial clustered breast cancer using published data.

Jonker MA, Jacobi CE, Hoogendoorn WE, Nagelkerke NJ, de Bock GH, van Houwelingen JC.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1479-85.

13.

Oral contraceptive use and BRCA penetrance: a case-only study.

Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, Haites N, Hart J, Peled R, Gafà L, Leggio L, Traina A, Amodio R, Primic-Zakelj M, Zadnik V, Veidebaum T, Tekkel M, Berrino F.

Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2107-13. doi: 10.1158/1055-9965.EPI-09-0024. Epub 2009 Jun 23.

14.

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators, Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.

PMID:
18095154
15.
16.

Genetics and the young woman with breast cancer.

Evans JP, Skrzynia C, Susswein L, Harlan M.

Breast Dis. 2005-2006;23:17-29. Review.

PMID:
16823163
17.

The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.

De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, Volorio S, Ravagnani F, Radice P, Peterlongo P.

Cancer Detect Prev. 2008;32(2):140-3. doi: 10.1016/j.cdp.2008.06.003. Epub 2008 Jul 21.

PMID:
18640791
18.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res. 2006;8(1):R12. Epub 2006 Feb 13.

19.
20.

[In cases of familial ovarian cancer, always consider the risk of breast cancer].

Kets CM, Niermeijer MF, Massuger LF, Hoogerbrugge N.

Ned Tijdschr Geneeskd. 2004 Aug 28;148(35):1709-11. Dutch.

PMID:
15468897

Supplemental Content

Support Center